Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Gene Therapy Pionee | Lexeo Therapeutics leads in rare cardiac diseases and Alzheimer's with innovative AAVrh10-based gene therapies, targeting high-impact medical needs |
Pipeline Potential | Explore Lexeo's three key programs: LX2006 for Friedreich's Ataxia, LX2020 for PKP2-ACM, and LX1001 for Alzheimer's, with crucial data expected in 2024 |
Regulatory Landscape | Learn how Lexeo navigates a favorable FDA environment, potentially streamlining development through single-arm trials and flexible approval pathways |
Market Outlook | Analyst price targets range from $24 to $28, reflecting optimism despite current market volatility and the speculative nature of gene therapy investments |
Metrics to compare | LXEO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLXEOPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.2x | −3.4x | −0.5x | |
PEG Ratio | −0.05 | 0.00 | 0.00 | |
Price/Book | 2.7x | 2.7x | 2.6x | |
Price / LTM Sales | - | 151.9x | 3.3x | |
Upside (Analyst Target) | 329.2% | 200.8% | 43.4% | |
Fair Value Upside | Unlock | 6.0% | 7.1% | Unlock |